Drug Trial Radar · NCT07722494
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Oct 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
Conditions
- Colorectal Cancer
Interventions
IBI363 + bevacizumabDrug
In this arm, patients will receive IBI363 plus bevacizumab
Investigator's choice of therapyDrug
In this arm, patients will receive Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Through out the study (an average of 2 years)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Wuhan, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.